PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9303604

[Silent ischemia].

I Castro·V D Castro·R Alclade·R Rodrigues·I Nesralla
View original source ↗Export metadata ↓

Abstract

The state of art in the treatment of silent myocardial ischemia is reviewed in such a way as to provide with the cardiologist information for the correct decision to be made in patients with ischemia, but without clinical symptoms of angina and its equivalents. Previewed-required, the concept, the classification and the diagnostic methods were reviewed. The prognosis, pharmacological treatment, intervention procedures and their results on the natural history of the disease are emphasised. It is recommended that the treatment of silent ischemia be done, at first, with primary and secondary prevention, and with pharmacological therapy. It is assumed that with the reduction of general ischemic episodes, survival can be individualized. New techniques have been introduced that modify the results in both the short and long term of these procedures.

Explore related subjects

Cardiovascular AgentsHumansMyocardial IschemiaMyocardial RevascularizationPrognosisEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Castro, V D Castro, R Alclade, R Rodrigues, I Nesralla. 1997. [Silent ischemia].. https://pubmed.ncbi.nlm.nih.gov/9303604/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure.

OBJECTIVES: We sought to assess whether in clinically stable patients with chronic heart failure (CHF) the prolongation (i.e., increase) of an initially short (< or = 125 ms) Doppler transmitral deceleration time (DT) of early filling obtained with long-term optimal oral therapy predicts a more favorable prognosis. BACKGROUND: It has been recently demonstrated that transmitral early DT is a powerful independent predictor of poor prognosis in patients with left ventricular dysfunction. However, DT may change over time according to loading conditions and medical treatment. METHOD: One hundred forty-four patients with CHF and a short DT (< or = 125 ms) underwent repeat Doppler echocardiographic study 6 months after the initial examination, while clinically stable with optimal oral therapy, and were then followed up for a mean period of 26 +/- 7 months. RESULTS: After 6 months, DT had not changed in 80 patients (group 1), whereas it was significantly prolonged (> 125 ms) in the remaining 64 patients (group 2). Baseline Doppler echocardiographic features were similar in the two groups. No changes were found after 6 months in group 1, whereas group 2 showed a slight but significant (p < 0.01) reduction in end-systolic volume, an improvement in left ventricular ejection fraction (p < 0.01) and a decrease (p < 0.01) in the degree of tricuspid regurgitation. During follow-up, 37% of patients in group 1 experienced cardiac death versus 11% in group 2 (p < 0.0005). By Cox model analysis, prolongation of a short DT emerged as the single best predictor of survival (chi-square 15.70). CONCLUSIONS: The prolongation of an initially short DT obtained with long-term optimal oral therapy predicts a more favorable outcome in clinically stable patients with CHF.

Cardiovascular Agents↗
PubMed1998

Stress echocardiography: recommendations for performance and interpretation of stress echocardiography. Stress Echocardiography Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography.

Cardiovascular stress testing remains the mainstay of provocative evaluation for patients with known or suspected coronary artery disease. Stress echocardiography has become a valuable means of cardiovascular stress testing. It plays a crucial role in the initial detection of coronary disease, in determining prognosis, and in therapeutic decision making. The purpose of this document is to outline the recommended methodology for stress echocardiography with respect to personnel and equipment as well as the clinical use of this recently developed technique. Specific limitations will also be discussed.

Cardiovascular Agents↗